RESUMEN
The antidiabetic effect of N. sativa seed ethanol extract (NSE) was assessed in Meriones shawi after development of diabetes. Meriones shawi were divided randomly into four groups: normal control, diabetic control, diabetic treated with NSE (2 g eq plant/kg) or with metformin (300 mg/kg) positive control, both administered by daily intragastric gavage for 4 weeks. Glycaemia and body weight were evaluated weekly. At study's end, an Oral Glucose Tolerance Test (OGTT) was performed to estimate insulin sensitivity. Upon sacrifice, plasma lipid profile, insulin, leptin, and adiponectin levels were assessed. ACC phosphorylation and Glut4 protein content were determined in liver and skeletal muscle. NSE animals showed a progressive normalization of glycaemia, albeit slower than that of metformin controls. Moreover, NSE increased insulinemia and HDL-cholesterol, compared to diabetic controls. Leptin and adiponectin were unchanged. NSE treatment decreased OGTT and tended to decrease liver and muscle triglyceride content. NSE stimulated muscle and liver ACC phosphorylation and increased muscle Glut4. These results confirm NSE's previously reported hypoglycaemic and hypolipidemic activity. More significantly, our data demonstrate that in vivo treatment with NSE exerts an insulin-sensitizing action by enhancing ACC phosphorylation, a major component of the insulin-independent AMPK signaling pathway, and by enhancing muscle Glut4 expression.
RESUMEN
We studied the effect of a 4-week intragastric gavage with a petroleum ether extract of Nigella sativa seeds on blood glucose, insulin and lipids in the normal rat. Petroleum ether extract caused a 25% reduction in food intake that translated into a transient weight loss. No sign of toxicity of the plant could be seen in vivo or in vitro. Fasting plasma glucose remained stable throughout Nigella sativa treatment. At the end of the 4-week treatment, Nigella sativa-treated rats had lower fasting plasma levels of insulin and triglycerides, and higher HDL-cholesterol as compared to pair-fed controls. Response to insulin was evaluated in hepatocytes isolated from animals of all groups by Western blot analysis of phosphorylated MAPK p44/42erk and PKB. In vivo Nigella sativa treatment resulted in greater dose-dependent activation of MAPK and PKB in response to insulin. These results suggest that the petroleum ether extract of Nigella sativa has a slight anorexic effect, and that it contains the hypolipidemic activity previously obtained with the plant. More significantly, our data demonstrate that in vivo treatment with the petroleum ether extract exerts an insulin-sensitizing action by enhancing the activity of the two major intracellular signal transduction pathways of the hormone's receptor.
Asunto(s)
Alcanos/uso terapéutico , Hiperlipidemias/tratamiento farmacológico , Insulina/sangre , Nigella sativa , Alcanos/aislamiento & purificación , Alcanos/farmacología , Animales , Glucemia/efectos de los fármacos , Glucemia/metabolismo , Hiperlipidemias/sangre , Masculino , Extractos Vegetales/aislamiento & purificación , Extractos Vegetales/farmacología , Extractos Vegetales/uso terapéutico , Ratas , Ratas Sprague-Dawley , SemillasRESUMEN
BACKGROUND: Type II diabetes and obesity are major health problems worldwide and aboriginal peoples are particularly at risk. To address this problem in Canadian native populations who find modern pharmaceuticals culturally inappropriate, our team is testing the traditional pharmacopeia of the James Bay Cree for anti-diabetic and anti-obesity activities. More specifically, the aim of the present study was to define the effects of traditional plants on intestinal glucose absorption, an under-appreciated anti-hyperglycaemic and anti-obesity activity. METHODS: Crude ethanol extracts of 17 Boreal forest medicinal plants were tested in vitro using the Caco-2 human enterocytic cell line and in vivo using an oral glucose tolerance test. RESULTS: Thirteen of seventeen extracts were observed to significantly inhibit uptake when administered simultaneously with (3)H-deoxyglucose. Inhibition was dose-dependent and, in a few cases, even surpassed that induced by a combination of the positive controls. To validate these effects in vivo, four plant extracts were administered by intragastric gavage at 250 mg/kg to normal rats simultaneously with a 3g/kg bolus of glucose. This resulted in a decrease in peak glycaemia by approximately 40% for two of them. Similarly, only 2 extracts reduced glucose transport after long term incubation and this could be related to reductions in the expression of SGLT-1 or GLUT-2 proteins. CONCLUSIONS: These findings indicate that competitive inhibition of intestinal glucose uptake can be achieved by crude extracts of medicinal plants. Such extracts could be taken with meals to control postprandial glycaemia and reduce caloric intake in high risk populations that are positively inclined towards traditional medicine.
Asunto(s)
Diabetes Mellitus Tipo 2/tratamiento farmacológico , Glucosa/metabolismo , Hipoglucemiantes/farmacología , Absorción Intestinal/efectos de los fármacos , Fitoterapia , Extractos Vegetales/farmacología , Plantas Medicinales , Animales , Células CACO-2 , Canadá , Prueba de Tolerancia a la Glucosa , Transportador de Glucosa de Tipo 2/metabolismo , Humanos , Hiperglucemia/tratamiento farmacológico , Hipoglucemiantes/toxicidad , Indígenas Norteamericanos , Masculino , Farmacopeas como Asunto , Extractos Vegetales/administración & dosificación , Extractos Vegetales/toxicidad , Ratas , Ratas Wistar , Transportador 1 de Sodio-Glucosa/metabolismoRESUMEN
Several medicinal plants that stimulate glucose uptake in skeletal muscle cells were identified from among species used by the Cree of Eeyou Istchee of northern Quebec to treat symptoms of diabetes. This study aimed to elucidate the mechanism of action of one of these products, the berries of Vaccinium vitis idaea, as well as to isolate and identify its active constituents using a classical bioassay-guided fractionation approach. Western immunoblot analysis in C2C12 muscle cells revealed that the ethanol extract of the berries stimulated the insulin-independent AMP-activated protein kinase (AMPK) pathway. The extract mildly inhibited ADP-stimulated oxygen consumption in isolated mitochondria, an effect consistent with metabolic stress and the ensuing stimulation of AMPK. This mechanism is highly analogous to that of Metformin. Fractionation guided by glucose uptake activity resulted in the isolation of ten compounds. The two most active, quercetin-3-O-glycosides, enhanced glucose uptake by 38-59% (50 muM; 18 h treatment) in the absence of insulin. Quercetin aglycone, a minor constituent, stimulated uptake by 37%. The quercetin glycosides and the aglycone stimulated the AMPK pathway at concentrations of 25-100 muM, but only the aglycone inhibited ATP synthase in isolated mitochondria (by 34 and 79% at 25 and 100 muM, respectively). This discrepancy suggests that the activity of the glycosides may require hydrolysis to the aglycone form. These findings indicate that quercetin and quercetin 3-O-glycosides are responsible for the antidiabetic activity of V. vitis crude berry extract mediated by AMPK. These common plant products may thus have potential applications for the prevention and treatment of insulin resistance and other metabolic diseases.
Asunto(s)
Proteínas Quinasas Activadas por AMP/metabolismo , Glucosa/metabolismo , Glicósidos/farmacología , Hipoglucemiantes/farmacología , Mioblastos Esqueléticos/efectos de los fármacos , Quercetina/farmacología , Vaccinium vitis-Idaea/química , Adenosina Trifosfato/metabolismo , Animales , Línea Celular , Diabetes Mellitus/dietoterapia , Diabetes Mellitus/prevención & control , Frutas/química , Glicósidos/química , Glicósidos/aislamiento & purificación , Hepatocitos/efectos de los fármacos , Hepatocitos/metabolismo , Concentración de Iones de Hidrógeno , Hipoglucemiantes/química , Hipoglucemiantes/aislamiento & purificación , Cinética , Masculino , Ratones , Mitocondrias Hepáticas/efectos de los fármacos , Mitocondrias Hepáticas/metabolismo , ATPasas de Translocación de Protón Mitocondriales/metabolismo , Mioblastos Esqueléticos/metabolismo , Concentración Osmolar , Extractos Vegetales/química , Extractos Vegetales/farmacología , Plantas Medicinales/química , Quebec , Quercetina/análogos & derivados , Quercetina/química , Quercetina/aislamiento & purificación , Ratas , Ratas WistarRESUMEN
AIM OF THE STUDY: Nigella sativa L. (Ranunculaceae) seeds have been used traditionally for centuries, notably for treating diabetes. MATERIALS AND METHODS: We studied the effects of the crude aqueous extract of Nigella sativa seeds on intestinal glucose absorption in vitro using a short-circuit current technique and in vivo using an oral glucose tolerance test. RESULTS: The aqueous extract of Nigella sativa (0.1 pg/ml to 100 ng/ml) exerted dose-dependent inhibition of sodium-dependent glucose transport across isolated rat jejunum. Maximal inhibition exceeded 80% and IC50 was close to 10 pg/ml. An oral glucose tolerance test was carried out in rats after the initial dose and after a 6-week treatment of Nigella sativa (2 g/(kg day)), and compared to metformin (300 mg/(kg day)). Chronic Nigella sativa treatment improved glucose tolerance as efficiently as metformin. Nigella sativa and metformin also reduced body weight without any toxic effect. CONCLUSIONS: To our knowledge, this is the first demonstration that Nigella sativa directly inhibits the electrogenic intestinal absorption of glucose in vitro. Together with the observed improvement of glucose tolerance and body weight in rats after chronic oral administration in vivo, these effects further validate the traditional use of Nigella sativa seeds against diabetes.
Asunto(s)
Peso Corporal/efectos de los fármacos , Glucosa/metabolismo , Hipoglucemiantes/farmacología , Absorción Intestinal/efectos de los fármacos , Nigella sativa , Extractos Vegetales/farmacología , Animales , Relación Dosis-Respuesta a Droga , Femenino , Prueba de Tolerancia a la Glucosa , Masculino , Metformina/farmacología , Ratas , Ratas Sprague-Dawley , SemillasRESUMEN
Incidence of type II diabetes is rapidly increasing worldwide. In order to identify complementary or alternative approaches to existing medications, we studied anti-diabetic properties of Vaccinium angustifolium Ait., a natural health product recommended for diabetes treatment in Canada. Ethanol extracts of root, stem, leaf, and fruit were tested at 12.5 microg/ml for anti-diabetic activity in peripheral tissues and pancreatic beta cells using a variety of cell-based bioassays. Specifically, we assessed: (1) deoxyglucose uptake in differentiated C2C12 muscle cells and 3T3-L1 adipocytes; (2) glucose-stimulated insulin secretion (GSIS) in beta TC-tet pancreatic beta cells; (3) beta cell proliferation in beta TC-tet cells; (4) lipid accumulation in differentiating 3T3-L1 cells; (5) protection against glucose toxicity in PC12 cells. Root, stem, and leaf extracts significantly enhanced glucose transport in C2C12 cells by 15-25% in presence and absence of insulin after 20 h of incubation; no enhancement resulted from a 1 h exposure. In 3T3 cells, only the root and stem extracts enhanced uptake, and this effect was greater after 1 h than after 20 h; uptake was increased by up to 75% in absence of insulin. GSIS was potentiated by a small amount in growth-arrested beta TC-tet cells incubated overnight with leaf or stem extract. However, fruit extracts were found to increase 3H-thymidine incorporation in replicating beta TC-tet cells by 2.8-fold. Lipid accumulation in differentiating 3T3-L1 cells was accelerated by root, stem, and leaf extracts by as much as 6.5-fold by the end of a 6-day period. Stem, leaf, and fruit extracts reduced apoptosis by 20-33% in PC12 cells exposed to elevated glucose for 96 h. These results demonstrate that V. angustifolium contains active principles with insulin-like and glitazone-like properties, while conferring protection against glucose toxicity. Enhancement of proliferation in beta cells may represent another potential anti-diabetic property. Extracts of the Canadian blueberry thus show promise for use as a complementary anti-diabetic therapy.
Asunto(s)
Arándanos Azules (Planta)/química , Hipoglucemiantes/farmacología , Células 3T3 , Animales , Línea Celular , Proliferación Celular/efectos de los fármacos , Citoprotección/efectos de los fármacos , Desoxiglucosa/metabolismo , Glucosa/metabolismo , Glucosa/toxicidad , Hipoglucemiantes/análisis , Insulina/metabolismo , Metabolismo de los Lípidos/efectos de los fármacos , Ratones , Extractos Vegetales/química , Extractos Vegetales/farmacologíaRESUMEN
Type II diabetes is a major health problem worldwide. Some populations, such as aboriginal peoples, are particularly at risk for this disease. In the Cree Nation of Quebec, Canada, prevalence in adults is approaching 20%, and the consequences are compounded by low compliance with modern medicine. In 2003, we conducted an ethnobotanical study of Cree medicinal plants used for the treatment of symptoms of diabetes. This served as the basis for a project designed to identify efficacious complementary treatment options more readily accepted by this population. The present study assesses the in vitro anti-diabetic potential of extracts from the 8 most promising plants to emerge from the ethnobotanical study. Cell-based bioassays were employed to screen for (i) potentiation of glucose uptake by skeletal muscle cells (C2C12) and adipocytes (3T3-L1); (ii) potentiation of glucose-stimulated insulin secretion (GSIS) and insulin production by pancreatic beta cells (INS 832/13); (iii) potentiation of triglyceride accumulation in differentiating 3T3-L1 cells; (iv) protection against glucose toxicity and glucose deprivation in pre-sympathetic neurons (PC12-AC). Additionally, anti-oxidant activity was measured biochemically by the diphenylpicrylhydrazyl (DPPH) reduction assay. All plant extracts potentiated basal or insulin-stimulated glucose uptake to some degree in muscle cells or adipocytes. Adipocyte differentiation was accelerated by 4 extracts. Five extracts conferred protection in PC12 cells. Three extracts displayed free radical scavenging activity similar to known anti-oxidants. None of the plant extracts enhanced GSIS or insulin content in INS 832/13 beta cells. It is concluded that the Cree pharmacopoeia contains several plants with significant anti-diabetic potential.